Currently out of the existing stock ratings of Ryan Deschner, 23 are a BUY (100%).

Ryan Deschner

Work Performance Price Targets & Ratings Chart

Analyst Ryan Deschner, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 34.03% that have a potential upside of 83.06% achieved within 222 days.

Ryan Deschner’s has documented 46 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LQDA, Liquidia Technologies at 04-Nov-2025.

Wall Street Analyst Ryan Deschner

Analyst best performing recommendations are on LQDA (LIQUIDIA TECHNOLOGIES).
The best stock recommendation documented was for LQDA (LIQUIDIA TECHNOLOGIES) at 5/27/2025. The price target of $29 was fulfilled within 99 days with a profit of $13.4 (85.9%) receiving and performance score of 8.68.

Average potential price target upside

ARDX Ardelyx LQDA Liquidia Technologies SPRY ARS Pharmaceuticals TRVI Trevi Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 16-Apr-2023

$9

$4.97 (123.33%)

$9

Buy Since 02-Mar-2016

$11

$6.97 (172.95%)

$14

Buy Since 02-May-2024

$10

$5.97 (148.14%)

$10

Buy Since 03-Mar-2025

$14

$9.97 (247.39%)

$17

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Ryan Deschner?

On 2024

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?